TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29876770
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (pantoprazole tablets, 40 mg)
Study: 29876770
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C (lansoprazole, 30 mg)
Study: 29876770
Drug: Group D
Normalized name: Prostaglandin group D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group D (esomeprazole, 20 mg)
Study: 29876770
Drug: Group E
Normalized name: Prostaglandin group E
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group E (rabeprazole, 10 mg)
Study: 26699168
Drug: Selexipag (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selexipag (maximum dose, 1600 μg twice daily)
Study: 20814970
Drug: Intravenous neridronate
Normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous neridronate (100 mg infusion for 2 consecutive days)
Study: 20814970
Drug: Intramuscular neridronate
Normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular neridronate (25 mg injection weekly for 2 months)
Study: 11023759
Drug: Imiquimod 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 2% cream
Study: 8828528
Drug: Optimal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal treatment of asthma based on the International Consensus Report on the Management of Asthma
Study: 1405323
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa (15, 50, or 150 U/kg) given intravenously every other day for four injections
Study: 3902377
Drug: New suppositories
Approvals — FDA: no, EMA: no, PMDA: no
Description: New suppositories (800 mg paracetamol, 16 mg codeine phosphate, 12.5 mg buclizine hydrochloride)
Study: 3902377
Drug: Old suppositories
Normalized name: Oldenlandia diffusa extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Old suppositories (800 mg paracetamol, 16 mg codeine phosphate, 12.5 mg buclizine hydrochloride)
Study: 3902377
Drug: New suppositories
Approvals — FDA: no, EMA: no, PMDA: no
Description: New suppositories
Study: 3902377
Drug: Old suppositories
Normalized name: Oldenlandia diffusa extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Old suppositories
Study: 31329819
Drug: Standard Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Administration
Study: 27919285
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (EN-PENS)
Study: 27919285
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (sham)
Study: 23740399
Drug: Local infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local infiltration with sodium bicarbonate as an adjunct to 2% lignocaine and 1:80,000 adrenaline
Study: 17418038
Drug: Progesterone (PG)
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone (PG) treatment group
Study: 15229622
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (Group D)
Study: 11980769
Drug: Trimegestone 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimegestone 0.25 mg/day combined with continuous E(2) 2 mg/day
Study: 11980769
Drug: Trimegestone 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimegestone 0.5 mg/day
Study: 11980769
Drug: Trimegestone 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimegestone 0.05 mg and 0.1 mg
Study: 10431997
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulfate (0.27 mmol/kg)
Study: 7587856
Drug: Preprandial regular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preprandial regular insulin combined with glibenclamide (group D)
Study: 7587856
Drug: Bedtime NPH
Normalized name: Buckley's Bedtime Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime NPH insulin combined with glibenclamide (group N)
Study: 22976655
Drug: 2-phase treatment
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2-phase treatment (Twin Block therapy followed by fixed appliance therapy with nonextraction)
Study: 22976655
Drug: 1-phase treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-phase treatment (fixed appliance therapy with extraction of 4 first premolars)
Study: 12750665
Drug: 2-phase treatment
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2-phase treatment
Study: 12750665
Drug: 1-phase treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-phase treatment
Study: 20210799
Drug: Whole Breast
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole Breast Radiation Therapy (WBRT)
Study: 15202583
Drug: Selective estrogen
Normalized name: Selective estrogen receptor modulator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective estrogen receptor modifiers
Study: 7944506
Drug: 400 IU
Normalized name: Vitamin D 400 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 IU of oral vitamin E (alpha-tocopherol acetate)
Study: 3225767
Drug: 5-mg immediate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-mg immediate release (IR) tablet given twice daily
Study: 3225767
Drug: 5-mg sustained-release
Normalized name: SR 121463
DrugBank: SR 121463 (DB05455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-mg sustained-release (SR) capsule formulations given daily
Study: 24981319
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol (CZP) 200 mg subcutaneously every 2 weeks (induction dosing: 400 mg at Weeks 0, 2, and 4)
Study: 24981319
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol (CZP) monotherapy
Study: 20974604
Drug: GW274150 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW274150 120 mg
Study: 20974604
Drug: GW274150 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW274150 60 mg (Part 2)
Study: 16141420
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (2 to 4 mg perindopril plus 2.0 to 2.5 mg indapamide for those without contraindications)
Study: 11952446
Drug: Intra-articular 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular 20 mL 0.5% bupivacaine with epinephrine (B + E‐group)
Study: 9772936
Drug: Indapamide 1.5
Normalized name: indapamide 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indapamide 1.5 mg sustained release
Study: 28658026
Drug: 150 mL/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mL/min
Study: 27063854
Drug: Mirabegron 50
Normalized name: mirabegron 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirabegron 50 mg plus Solifenacin 5 mg
Study: 25189764
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy (IIT) with blood glucose target between 4.4 and 6 mmol.L(‐1)
Study: 25189764
Drug: Conventional glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional glucose management with blood glucose target between 5.5 and 9 mmol.L(‐1)
Study: 15099664
Drug: Buprenorphine/naloxone (32/8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine/naloxone (32/8 mg)
Study: 15099664
Drug: Buprenorphine/naloxone (16/4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine/naloxone (16/4 mg)
Study: 15099664
Drug: Buprenorphine/naloxone (8/2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine/naloxone (8/2 mg)
Study: 12238830
Drug: Sotalol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol (80 mg twice daily for 5 days starting from the morning of the first postoperative day)
Study: 12238830
Drug: Magnesium (1.5
Normalized name: bicarb dialy soln 11 without K calcium (2.5 mEq/L)-magnesium (1.5 mEq/L) HEMODIALYS SOLUTION, NON-ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium (1.5 g daily for 6 days starting in the operating room just before cardiopulmonary bypass)
Study: 12238830
Drug: No antiarrhythmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antiarrhythmic agents (Control group)
Study: 7696074
Drug: Edrophonium 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium 0.75 mg kg‐1 administered 5 or 10 min after mivacurium, or when T1 had recovered to 5, 10, 25 or 50% of control.
Study: 29511807
Drug: D-amphetamine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-amphetamine (40 mg)
Study: 29511807
Drug: lisdexamfetamine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: lisdexamfetamine (100 mg)
Study: 23939631
Drug: Sotatercept 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotatercept 0.3 mg/kg
Study: 26370220
Drug: Sotatercept 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotatercept 0.5 mg/kg
Study: 23939631
Drug: Sotatercept 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotatercept 0.1 mg/kg
Study: 24608361
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (MgSO4) 60 mg/kg
Study: 15213033
Drug: L-Rhamnose
Normalized name: L-rhamnose isomerase
DrugBank: Rhamnose (DB02961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Rhamnose
Study: 9681082
Drug: Dexamethasone plus
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone plus granisetron (1 mg b.d. p.o.)
Study: 9681082
Drug: Dexamethasone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (8 mg b.d. p.o.)
Study: 356968
Drug: Intensive C.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive C. parvum immunotherapy
Study: 356968
Drug: Nonintensive C.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonintensive C. parvum immunotherapy
Study: 25975816
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg luseogliflozin + 30 mg pioglitazone
Study: 25975816
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg luseogliflozin + 50 mg miglitol
Study: 25975816
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg luseogliflozin + 1 mg glimepiride
Study: 25975816
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg luseogliflozin + 250 mg metformin
Study: 25975816
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg luseogliflozin + 50 mg sitagliptin
Study: 25975816
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg luseogliflozin + 0.6 mg voglibose
Study: 23118347
Drug: Control (drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (drugs with inert CYP effects)
Study: 19665279
Drug: Gonadotrophin-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotrophin-releasing hormone analogue (tryptorelin or leuprorelin, 3.75 mg every 28 days)
Study: 19665279
Drug: Continuous low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Continuous low-dose monophasic oral contraceptives (ethynilestradiol, 0.03 mg plus gestoden, 0.75 mg)
Study: 17052809
Drug: Enteral nutrition
Normalized name: ENTERAL NUTRITION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral nutrition enriched with carotenoids (3-mg/1500kcal) for 3 months
Study: 7831376
Drug: HA-1A treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: HA-1A treatment
Study: 3078426
Drug: Nifedipine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (4 mcg/Kg/L) added to cold potassium cardioplegia
Study: 16775510
Drug: Ethanol-water solution
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol-water solution (ET)
Study: 15181040
Drug: r‐metHuLeptin 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: r‐metHuLeptin 0.1 mg/kg
Study: 15181040
Drug: r‐metHuLeptin 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: r‐metHuLeptin 0.3 mg/kg
Study: 15181040
Drug: r‐metHuLeptin 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: r‐metHuLeptin 1.0 mg/kg
Study: 15181040
Drug: r‐metHuLeptin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: r‐metHuLeptin (all doses)
Study: 11303370
Drug: Lansoprazole and
Normalized name: Lansoprazole and naproxen only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole and two antibacterial agents chosen according to susceptibility test
Study: 11303370
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy based on proton pump inhibitor and two antibiotics
Study: 11303370
Drug: Gastric-mucosal culture
Normalized name: gastric mucins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastric-mucosal culture testing for sensitivity of H. pylori to antibiotics
Study: 8287568
Drug: hGH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: hGH treatment (group I) for 12 months
Study: 8287568
Drug: hGH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: hGH treatment (group I)
Study: 22724427
Drug: 0.91 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.91 ml/kg vodka
Study: 22724427
Drug: 1.82 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.82 ml/kg energy drink
Study: 2067362
Drug: Protamine pretreatment
Normalized name: protamines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protamine pretreatment (PP) 2 mg/kg
Study: 29030065
Drug: Diuretic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic treatment (40mg bolus of furosemide)
Study: 29030065
Drug: Volume expansion
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volume expansion (500mL of saline infusion)
Study: 15365927
Drug: Ketorolac and
Normalized name: Ketorolac and phenylephrine only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac and opioid analgesics
Study: 2453744
Drug: Acebutolol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol (400 mg, twice daily for 24 hours)
Study: 2453744
Drug: Acebutolol (480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol (480 mg, twice daily for 3 weeks)
Study: 2453744
Drug: Acebutolol (acute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol (acute and long-term treatment)
Study: 26329656
Drug: Dexmedetomidine (DEX)
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine (DEX) with low dosage of fentanyl (15 μg/kg)
Study: 26329656
Drug: High dosage
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dosage of fentanyl (30 μg/kg) with normal saline (control group)
Study: 24010549
Drug: Moderate red
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate red wine intake (250 mL/day for 4 weeks)
Study: 14673053
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of oral paroxetine hydrochloride daily
Study: 1424424
Drug: Nicorandil (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil (10 to 60 mg)
Study: 6731879
Drug: 4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/kg of cimetidine only
Study: 6731879
Drug: 0.15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg/kg of metoclopramide only
Study: 6731879
Drug: 4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/kg of cimetidine and 0.15 mg/kg of metoclopramide
Study: 31087542
Drug: TCZ‐SC 162
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCZ‐SC 162 mg qw
Study: 18602824
Drug: Bovine colostrum
Normalized name: Bovine Colostrum
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine colostrum (5 g, twice daily for 4 weeks)
Study: 16429095
Drug: Parents who
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parents who responded to antidepressant therapy (defined as at least a 40% reduction in depressive symptoms)
Study: 16429095
Drug: Parents who
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parents who did not respond to antidepressant therapy
Study: 16429095
Drug: Parents who
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parents who responded to treatment
Study: 16429095
Drug: Parents who
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parents who did not respond to treatment
Study: 1426499
Drug: Progesterone pessaries
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone pessaries 100 mg b.d. from 48 hours prior to embryo transfer and continued throughout the luteal phase
Study: 30504510
Drug: DMARD tapering
Normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DMARD tapering by 50% (arm 2)
Study: 30504510
Drug: Stopping DMARD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stopping DMARD after tapering (arm 3)
Study: 30504510
Drug: Full-dose DMARD
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose DMARD treatment
Study: 30504510
Drug: Tapering and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapering and stopping DMARD in low-risk relapse group
Study: 27259714
Drug: Chemotherapy of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy of physician's choice plus trastuzumab (gemcitabine, capecitabine, or vinorelbine)
Study: 22512435
Drug: Testosterone therapy
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone therapy (1000 mg testosterone undecanoate intramuscular injections at 0, 6, and 12 weeks)
Study: 15949795
Drug: Topical 0.1%
Normalized name: adapalene topical 0.1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.1% diclofenac
Study: 12385927
Drug: Therapeutic alpha-blockers
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic alpha-blockers
Study: 1801386
Drug: Otovent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Otovent treatment for two weeks
Study: 7230728
Drug: Aspirin treatment
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin treatment (1.5 g/day)
Study: 8938176
Drug: Phenprocoumon treatment
Normalized name: phenprocoumon
DrugBank: Phenprocoumon (DB00946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenprocoumon treatment
Study: 7230728
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment groups after one year
Study: 19491796
Drug: Aqua Maris
Normalized name: Aqua Maris
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqua Maris nasal spray (thrice daily)
Study: 23754628
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy alone (Control)
Study: 17955784
Drug: Donepezil, Galantamine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil, Galantamine, Rivastigmine (acetylcholinesterase inhibitors)
Study: 17955784
Drug: Memantine (glutamate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine (glutamate antagonist)
Study: 17955784
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of acetylcholinesterase inhibitors or memantine
Study: 10601178
Drug: DHEA (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA (150 mg/day)
Study: 10601178
Drug: DHEA (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA (50 mg acute ingestion)
Study: 31686175
Drug: Nicotine (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (7 mg/24 h, transdermally) and galantamine (4 mg, p.o.) combined
Study: 31686175
Drug: Nicotine alone
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine alone (7 mg/24 h, transdermally)
Study: 31686175
Drug: Galantamine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine alone (4 mg, p.o.)
Study: 31686175
Drug: Galantamine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine (4 mg, p.o.)
Study: 28251402
Drug: BRJ (140
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRJ (140 ml concentrated nitrate-rich beetroot juice, 12.5 mmol nitrate)
Study: 26198373
Drug: Gemcitabine 1000
Normalized name: gemcitabine 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1000 mg/m² plus vinorelbine 60 mg/m²
Study: 26198373
Drug: Vinorelbine doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine doses per kg LBM
Study: 26198373
Drug: Dose reduction
Normalized name: Rebetron Combination Package for Rebetol Dose Reduction, Intron A 6,000,000 UNT/ML Multi-Dose Vial / 42 Rebetol Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose reduction and/or stop of treatment
Study: 16531896
Drug: Antioxidant supplementation
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplementation (10,000 IU beta-carotene, 200 IU alpha-tocopherol acetate, 250 mg ascorbic acid, 50 microg selenium, 15 mg zinc)
Study: 15193678
Drug: Fondaparinux 4
Normalized name: Fondaparinux
DrugBank: Fondaparinux (DB00569)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fondaparinux 4 mg once daily
Study: 15193678
Drug: Fondaparinux 8
Normalized name: Fondaparinux
DrugBank: Fondaparinux (DB00569)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fondaparinux 8 mg once daily
Study: 15193678
Drug: Fondaparinux 12
Normalized name: fondaparinux 12.5 mg/mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fondaparinux 12 mg once daily
Study: 15193678
Drug: Fondaparinux 2.5
Normalized name: FONDAPARINUX 2.5MG/0.5ML INJ SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fondaparinux 2.5 mg once daily (per-protocol analysis)
Study: 15193678
Drug: Fondaparinux 4
Normalized name: Fondaparinux
DrugBank: Fondaparinux (DB00569)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fondaparinux 4 mg once daily (per-protocol analysis)
Study: 15193678
Drug: Fondaparinux 8
Normalized name: Fondaparinux
DrugBank: Fondaparinux (DB00569)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fondaparinux 8 mg once daily (per-protocol analysis)
Study: 15193678
Drug: Fondaparinux 12
Normalized name: fondaparinux 12.5 mg/mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fondaparinux 12 mg once daily (per-protocol analysis)